Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Oct 1;24(1):160–165. doi: 10.1111/dom.14547

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

A, Neutralization antibodies and CD4+ T cells producing tumor necrosis factor‐α (TNF‐α), interleukin‐2 (IL‐2) and interferon‐γ (IFNγ) in type 2 diabetes (T2D) patients with poor glycaemic control at baseline (vaccination day) and with glycated haemoglobin (HbA1c) <7% (HbA1c 8.1 ± 0.7 to 6.6% ± 0.4%) and HbA1c >7% (HbA1c 8.2 ± 0.8 to 8.3% ± 1.1%) at follow‐up (52 days after the second vaccination dose). Boxplots show the median, 25th and 75th percentiles, range, and extreme values). *P < 0.05 vs. T2D patients with HbA1c <7% at follow‐up. B, Regression analysis of HbA1c level changes (vaccination day and 52 days after second vaccination dose) and CD4+ T‐cell response changes (21 and 52 days after the second vaccine dose)